Stem cell markers (cytokeratin 15, cytokeratin 19 and p63) in in situ and invasive cutaneous epithelial lesions

Modern Pathology

Volumn 24, Issue 1, 2011, Pages 90-97

  Abbas, Ossama ^a   Richards, Joanna E ^a   Yaar, Ron ^a   Mahalingam, Meera ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

actinic keratosis; bowenoid papulosis; CK15; CK19; p63; squamous cell carcinoma; squamous cell carcinoma in situ

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 15; CYTOKERATIN 19; PROTEIN P63;

ACTINIC KERATOSIS; ARTICLE; BOWENOID PAPULOSIS; CARCINOMA IN SITU; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; STEM CELL;

EID: 78650920411     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.180     Document Type: Article

References (40)

1. Abbas O, Mahalingam M. Epidermal stem cells: practical perspectives and potential uses. Br J Dermatol 2009;161:228-236.
2. Kloepper JE, Tiede S, Brinckmann J, et al. Immuno-phenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Exp Dermatol 2008;17:592-609.
3. Kamstrup MR, Gniadecki R, Skovgaard GL. Putative cancer stem cells in cutaneous malignancies. Exp Dermatol 2007;16:297-301.
4. Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20:102-107.
5. Kanoh M, Amoh Y, Sato Y, et al. Expression of the hair stem cell-specific marker nestin in epidermal and follicular tumors. Eur J Dermatol 2008;18:518-523.
6. Braun KM, Niemann C, Jensen UB, et al. Manipulation of stem cell proliferation and lineage commitment: visualisation of label-retaining cells in whole mounts of mouse epidermis. Development 2003;130: 5241-5255.
7. Lyle S, Christofidou-Solomidou M, Liu Y, et al. The C8 144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 1998;111:3179-3188.
8. Hoang MP, Keady M, Mahalingam M. Stem cell markers (cytokeratin 15, CD34 and nestin) in primary scarring and nonscarring alopecia. Br J Dermatol 2009; 160:609-615.
9. Pozdnyakova O, Mahalingam M. Involvement of the bulge region in primary scarring alopecia. J Cutan Pathol 2008;35:922-925.
10. Lyle S, Christofidou-Solomidou M, Liu Y, et al. Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc 1999;4:296-301.
11. Michel M, Török N, Godbout MJ, et al. Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci 1996;109:1017-1028.
12. Morris RJ. A perspective on keratinocyte stem cells as targets for skin carcinogenesis. Differentiation 2004;72: 381-386.
13. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001;98:3156-3161.
14. Reis-Filho JS, Torio B, Albergaria A, et al. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002;29:517-523. (Pubitemid 35193295)
15. Koster MI, Kim S, Roop DR. p63 deficiency: a failure of lineage commitment or stem cell maintenance? J Investig Dermatol Symp Proc 2005;10:118-123.
16. Jih DM, Lyle S, Elenitsas R, et al. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J Cutan Pathol 1999;26:113-118.
17. Bieniek R, Lazar AJ, Photopoulos C, et al. Sebaceous tumours contain a subpopulation of cells expressing the keratin 15 stem cell marker. Br J Dermatol 2007;156:378-380.
18. Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol 2008;21:178-185.
19. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-140.
20. Tiede S, Kloepper JE, Bodo E, et al. Hair follicle stem cells: walking the maze. Eur J Cell Biol 2007;86: 355-376.
21. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005;21:605-631.
22. Lechler T, Fuchs E. Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature 2005;437:275-280.
23. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996;87:1539-1548.
24. Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000;95: 1007-1013.
25. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
26. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994;1: 661-673.
27. Oliveira LR, Jeffrey SS, Ribeiro-Silva A. Stem cells in human breast cancer. Histol Histopathol 2010;25: 371-385.
28. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells 2009;28:7-12.
29. Zhong LP, Chen WT, Zhang CP, et al. Increased CK19 expression correlated with pathologic differentiation grade and prognosis in oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:377-384.
30. Takeda T, Sugihara K, Hirayama Y, et al. Immuno-histological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 2006;35:369-375.
31. Raju RR, Goldblum JR, Hart WR. Pagetoid squamous cell carcinoma in situ (pagetoid Bowen's disease) of the external genitalia. Int J Gynecol Pathol 2003;22: 127-135.
32. Chen S, Takahara M, Kido M, et al. Increased expression of an epidermal stem cell marker, cytoker-atin 19, in cutaneous squamous cell carcinoma. Br J Dermatol 2008;159:952-955.
33. Martens JE, Arends J, Van der Linden PJ, et al. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. Anticancer Res 2004;24: 771-775.
34. Levrero M, De Laurenzi V, Costanzo A, et al. The p53/ p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000;113:1661-1670.
35. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001;98:3156-3161.
36. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002;9:280-289.
37. Tsujita-Kyutoku M, Kiuchi K, Danbara N, et al. p63 expression in normal human epidermis and epidermal appendages and their tumors. J Cutan Pathol 2003;30: 11-17.
38. Wrone DA, Yoo S, Chipps LK, Moy RL. The expression of p63 in actinic keratoses, seborrheic keratosis, and cutaneous squamous cell carcinomas. Dermatol Surg 2004;30:1299-1302.
39. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol 2006;33:413-417.
40. Hoffman RM. The pluripotency of hair follicle stem cells. Cell Cycle 2006;5:232-233.